John F Deeken1,2, Jan H Beumer3,4,5, Nicole M Anders6, Teresia Wanjiku6, Milan Rusnak1, Michelle A Rudek7. 1. Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. 2. INOVA Comprehensive Cancer and Research Institute, Virginia Commonwealth University, INOVA Campus, Falls Church, VA, USA. 3. Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA. 4. Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 5. Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. 6. The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, Bunting-Blaustein Cancer Research Bldg. Room 1M52, Baltimore, MD, 21231-1000, USA. 7. The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, Bunting-Blaustein Cancer Research Bldg. Room 1M52, Baltimore, MD, 21231-1000, USA. mrudek2@jhmi.edu.
Abstract
PURPOSE: Prevalence of non-AIDS-defining cancers (NADCs) has increased in the era of potent antiretroviral treatments. Incidence rates of NADCs now exceed AIDS-defining cancers in HIV-positive patients. Treatment of NADCs may be complicated by interactions between antiretrovirals and chemotherapy mostly via inhibition or induction of CYP3A4. Erlotinib is used to treat non-small cell lung and pancreatic cancer and is primarily metabolized by CYP3A4 into multiple products including the active metabolite (OSI-420). Preclinical in vivo assessment was performed to gain a better understanding of CYP3A4-mediated interactions between antiretrovirals and erlotinib. METHODS: Erlotinib (50 mg/kg p.o.) was administered to male FVB mice in the presence and absence of dexamethasone (10 mg/kg p.o. QDx4), efavirenz (25 mg/kg p.o. QDx4), ketoconazole (50 mg/kg p.o.), or ritonavir (12.5 mg/kg p.o.). Blood samples were collected to characterize exposure (AUC). RESULTS: Administration of erlotinib with CYP3A4 inducers (dexamethasone) and inhibitors (ketoconazole and ritonavir) resulted in significant alterations in erlotinib exposure. Ketoconazole and ritonavir resulted in a 1.7- and 3.0-fold increase in erlotinib AUC, respectively, while dexamethasone results in a 0.6-fold decrease in erlotinib AUC. The CYP3A4 inducer efavirenz did not have a significant effect on erlotinib exposure. CONCLUSION: CYP3A4 inducers and inhibitors altered the exposure of erlotinib. Until a definitive clinical trial is performed, erlotinib should be used with caution in patients on a ritonavir-containing antiretroviral regimen, while standard doses may be appropriate for patients on an efavirenz-containing antiretroviral regimen.
PURPOSE: Prevalence of non-AIDS-defining cancers (NADCs) has increased in the era of potent antiretroviral treatments. Incidence rates of NADCs now exceed AIDS-defining cancers in HIV-positivepatients. Treatment of NADCs may be complicated by interactions between antiretrovirals and chemotherapy mostly via inhibition or induction of CYP3A4. Erlotinib is used to treat non-small cell lung and pancreatic cancer and is primarily metabolized by CYP3A4 into multiple products including the active metabolite (OSI-420). Preclinical in vivo assessment was performed to gain a better understanding of CYP3A4-mediated interactions between antiretrovirals and erlotinib. METHODS:Erlotinib (50 mg/kg p.o.) was administered to male FVB mice in the presence and absence of dexamethasone (10 mg/kg p.o. QDx4), efavirenz (25 mg/kg p.o. QDx4), ketoconazole (50 mg/kg p.o.), or ritonavir (12.5 mg/kg p.o.). Blood samples were collected to characterize exposure (AUC). RESULTS: Administration of erlotinib with CYP3A4 inducers (dexamethasone) and inhibitors (ketoconazole and ritonavir) resulted in significant alterations in erlotinib exposure. Ketoconazole and ritonavir resulted in a 1.7- and 3.0-fold increase in erlotinib AUC, respectively, while dexamethasone results in a 0.6-fold decrease in erlotinib AUC. The CYP3A4 inducer efavirenz did not have a significant effect on erlotinib exposure. CONCLUSION:CYP3A4 inducers and inhibitors altered the exposure of erlotinib. Until a definitive clinical trial is performed, erlotinib should be used with caution in patients on a ritonavir-containing antiretroviral regimen, while standard doses may be appropriate for patients on an efavirenz-containing antiretroviral regimen.
Entities:
Keywords:
AIDS; Drug interaction; Efavirenz; Erlotinib; Ritonavir
Authors: L L von Moltke; D J Greenblatt; B W Granda; G M Giancarlo; S X Duan; J P Daily; J S Harmatz; R I Shader Journal: J Clin Pharmacol Date: 2001-01 Impact factor: 3.126
Authors: Michelle A Rudek; Cathy Y Chang; Kenneth Steadman; Michael D Johnson; Naveen Desai; John F Deeken Journal: Cancer Chemother Pharmacol Date: 2014-02-02 Impact factor: 3.333
Authors: Marta Hamilton; Julie L Wolf; Daniel W Drolet; Scott H Fettner; Ashok K Rakhit; Karsten Witt; Bert L Lum Journal: Cancer Chemother Pharmacol Date: 2014-01-29 Impact factor: 3.333
Authors: Ming Zhao; Ping He; Michelle A Rudek; Manuel Hidalgo; Sharyn D Baker Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2003-08-15 Impact factor: 3.205
Authors: Brian C Jensen; Traci L Parry; Wei Huang; Amro Ilaiwy; James R Bain; Michael J Muehlbauer; Sara K O'Neal; Cam Patterson; Gary L Johnson; Monte S Willis Journal: Metabolites Date: 2017-06-22
Authors: Timothy J Stuhlmiller; Jon S Zawistowski; Xin Chen; Noah Sciaky; Steven P Angus; Sean T Hicks; Traci L Parry; Wei Huang; Ju Youn Beak; Monte S Willis; Gary L Johnson; Brian C Jensen Journal: J Am Heart Assoc Date: 2017-10-19 Impact factor: 5.501
Authors: JoEllyn M McMillan; Denise A Cobb; Zhiyi Lin; Mary G Banoub; Raghubendra S Dagur; Amanda A Branch Woods; Weimin Wang; Edward Makarov; Ted Kocher; Poonam S Joshi; Rolen M Quadros; Donald W Harms; Samuel M Cohen; Howard E Gendelman; Channabasavaiah B Gurumurthy; Santhi Gorantla; Larisa Y Poluektova Journal: J Pharmacol Exp Ther Date: 2018-02-23 Impact factor: 4.030